<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00963690</url>
  </required_header>
  <id_info>
    <org_study_id>CL-0100-01</org_study_id>
    <nct_id>NCT00963690</nct_id>
  </id_info>
  <brief_title>Evaluation of the CloSys Closure System as an Adjunct to Standard Compression</brief_title>
  <official_title>CloSys Hemostatic Device U.S. Multi-Center Clinical Investigation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CloSys Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eminence Clinical Research, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CloSys Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of the CloSys Hemostatic&#xD;
      Device designed to stop bleeding after an interventional procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To analyze the time to hemostasis (time to stop bleeding), time to ambulation (time to walk)&#xD;
      and adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of funding&#xD;
  </why_stopped>
  <start_date type="Actual">August 2009</start_date>
  <completion_date type="Actual">May 30, 2013</completion_date>
  <primary_completion_date type="Actual">April 30, 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to hemostasis</measure>
    <time_frame>1 Hour</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to ambulation</measure>
    <time_frame>6 Hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Within 30 days after procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Sealing the Arteriotomy</condition>
  <arm_group>
    <arm_group_label>CloSys HD with standard compression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CloSys Arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard compression alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Manual compression arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CloSys Hemostatic Device (HD)</intervention_name>
    <description>Deploy CloSys HD to achieve hemostasis</description>
    <arm_group_label>CloSys HD with standard compression</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard compression</intervention_name>
    <description>Use standard compression to achieve hemostasis</description>
    <arm_group_label>CloSys HD with standard compression</arm_group_label>
    <arm_group_label>Standard compression alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria&#xD;
&#xD;
        All answers must be YES to be eligible for the study:&#xD;
&#xD;
          1. Subject is ≥ 18 years of age;&#xD;
&#xD;
          2. Subject is willing and able to provide informed consent;&#xD;
&#xD;
          3. Subject is able to ambulate pre-procedure without difficulty;&#xD;
&#xD;
          4. Subject is able to remain supine for an extended period of time;&#xD;
&#xD;
          5. Subject is willing and able to comply with the requirements of the study protocol,&#xD;
             including all follow-up visit evaluations;&#xD;
&#xD;
        General Exclusion Criteria&#xD;
&#xD;
        All answers must be NO to be eligible for the study:&#xD;
&#xD;
          1. Subject has a systolic blood pressure (SBP) ≥ 160 mmHg despite medical therapy;&#xD;
&#xD;
          2. Subject has a diastolic blood pressure (DBP) ≥ 100 mmHg despite medical therapy;&#xD;
&#xD;
          3. Subject has received thrombolytic therapy, such as streptokinase, urokinase, retavase,&#xD;
             tenecteplase, or tPA, within 24 hours of the scheduled procedure;&#xD;
&#xD;
          4. Subject is lactating;&#xD;
&#xD;
          5. Subject has a life expectancy of less than one (1) year;&#xD;
&#xD;
          6. The percutaneous intervention was an emergent procedure;&#xD;
&#xD;
          7. Subject has a known coagulopathy disorder, including, but not limited to, hemophilia,&#xD;
             sickle cell disease, or von Willebrand disease;&#xD;
&#xD;
          8. Subject has a known diagnosis of an auto-immune disease;&#xD;
&#xD;
          9. Subject has a known or suspected diagnosis of vasculitis;&#xD;
&#xD;
         10. Subject currently has an infection of any kind;&#xD;
&#xD;
         11. Subject does not have either a posterior Tibialis (PT) or dorsalis pedis (DP) pulse by&#xD;
             doppler in ipsilateral extremity;&#xD;
&#xD;
         12. Subject has critical limb ischemia and/or severe peripheral vascular disease as&#xD;
             identified by rest pain and/or gangrene;&#xD;
&#xD;
         13. Rutherford category five (5) or six (6);&#xD;
&#xD;
         14. Subject is currently or within the last thirty (30) days participating in another&#xD;
             investigational drug or device study;&#xD;
&#xD;
         15. Subject is unavailable for follow-up;&#xD;
&#xD;
         16. Subject has known allergy or previous intolerance to Protamine Sulfate;&#xD;
&#xD;
         17. Subject has known allergy to shellfish;&#xD;
&#xD;
         18. Subject has had a previous closure device in the ipsilateral side within the last&#xD;
             ninety (90) days;&#xD;
&#xD;
         19. Prior intervention or surgical procedure to the access site within the last six (6)&#xD;
             months;&#xD;
&#xD;
         20. Subject has a planned intervention or surgical procedure prior to completion of the&#xD;
             thirty (30) day follow-up visit;&#xD;
&#xD;
         21. Subject has received a low molecular weight (LMWH) heparin, such as, Enoxaparin sodium&#xD;
             (Lovenox, Xaparin and Clexane) within the past twelve (12) hours;&#xD;
&#xD;
         22. Body mass index (BMI) &gt; 45 or &lt; 20;&#xD;
&#xD;
         23. The investigator determines the subject is otherwise not an appropriate subject for&#xD;
             the study; 5.3.2.1 Laboratory Values Exclusion Criteria&#xD;
&#xD;
        All answers must be NO to be eligible for the study:&#xD;
&#xD;
        Within seven (7) days prior to interventional procedure or according to standard of care&#xD;
        for percutaneous interventional procedures requiring contrast and angiography:&#xD;
&#xD;
          1. Subject is known to be, or suspected to be, pregnant (verified with a urine/blood&#xD;
             pregnancy test);&#xD;
&#xD;
          2. Subject's pre-procedural platelet count &lt; 100,000 103/ul;&#xD;
&#xD;
          3. Subject's hematocrit &lt; 28%;&#xD;
&#xD;
          4. Subject's hemoglobin &lt; 10 g/dL;&#xD;
&#xD;
          5. Subject's serum creatinine ≥ 2.5 mg/dL;&#xD;
&#xD;
          6. Prothrombin Time (PT) is not within normal limits;&#xD;
&#xD;
          7. Partial Thromboplastin Time (PTT) is not within normal limits;&#xD;
&#xD;
          8. For subjects taking warfarin (Coumadin): The subject on warfarin within 30 days has an&#xD;
             INR ≥ 1.8 at the time of procedure;&#xD;
&#xD;
        post - Interventional Procedure Inclusion Criteria&#xD;
&#xD;
        All answers must be YES to be eligible for the study:&#xD;
&#xD;
          1. Subject has undergone a percutaneous interventional procedure utilizing a femoral&#xD;
             arterial access;&#xD;
&#xD;
          2. Heparin is administered for anti-coagulation during the procedure;&#xD;
&#xD;
          3. Subject has an ACT ≥ 225 seconds and &lt; 350 seconds;&#xD;
&#xD;
          4. Subject's arterial introducer sheath is 5 Fr, 6 Fr or 7 Fr;&#xD;
&#xD;
          5. Subject's arterial introducer sheath has an overall length of ≤ 15.0 cm;&#xD;
&#xD;
          6. Subject's SBP &lt; 160 mmHg;&#xD;
&#xD;
          7. Subject's DBP &lt; 100mmHg;&#xD;
&#xD;
          8. Subject's physical, mental, and clinical status is stable and allows for ambulation&#xD;
             assessment four (4) hours following removal of introducer sheath; 5.3.4 Post -&#xD;
             Interventional Procedure Exclusion Criteria&#xD;
&#xD;
        All answers must be NO to be eligible for the study:&#xD;
&#xD;
        5.3.4.1 General Exclusion Criteria&#xD;
&#xD;
          1. Subject experienced cardiogenic shock before, during, or immediately after the&#xD;
             interventional procedure;&#xD;
&#xD;
          2. Subject has bleeding around the sheath prior to sheath removal;&#xD;
&#xD;
          3. Subject has a pseudoaneurysm before sheath removal;&#xD;
&#xD;
          4. Subject has a palpable hematoma before sheath removal;&#xD;
&#xD;
          5. Subject has evidence of a retroperitoneal bleed prior to sheath removal;&#xD;
&#xD;
          6. Subject experienced double wall punctures during vascular access;&#xD;
&#xD;
          7. Subject experienced multiple arterial punctures (&gt; 1) during vascular access;&#xD;
&#xD;
          8. Subject has ipsilateral venous sheaths;&#xD;
&#xD;
          9. Subject had intraprocedural therapeutic thrombolysis;&#xD;
&#xD;
         10. Subject received bivalirudin(Angiomax®) before, during, or after the intervention;&#xD;
&#xD;
         11. Subject received Protamine Sulfate IV to reverse heparin received during procedure;&#xD;
&#xD;
         12. Subject has a suspected bacterial contamination of the access site;&#xD;
&#xD;
         13. Arterial access was obtained in or near a vascular graft;&#xD;
&#xD;
         14. Subject's percutaneous intervention was for the treatment of an acute myocardial&#xD;
             infarction (MI);&#xD;
&#xD;
        Angiographic Eligibility Criteria Angiographic Inclusion Criteria&#xD;
&#xD;
        All answers must be YES to be eligible for the trial:&#xD;
&#xD;
          1. Arterial access was obtained above the femoral bifurcation;&#xD;
&#xD;
          2. Arterial access was obtained below the inguinal ligament; Angiographic Exclusion&#xD;
             Criteria&#xD;
&#xD;
        All answers must be NO to be eligible for the trial:&#xD;
&#xD;
          1. Common femoral artery &gt; 50% narrowing due to calcification or plaque;&#xD;
&#xD;
          2. Arteriovenous fistula present;&#xD;
&#xD;
          3. Other complication noted on femoral angiogram.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Adams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rex Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rex Healthcare - Rex Heart and Vascular Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>August 12, 2009</study_first_submitted>
  <study_first_submitted_qc>August 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2009</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

